HUE029982T2 - CD28 kötésre monovalens kompozíciók és felhasználási eljárások - Google Patents

CD28 kötésre monovalens kompozíciók és felhasználási eljárások Download PDF

Info

Publication number
HUE029982T2
HUE029982T2 HUE09790582A HUE09790582A HUE029982T2 HU E029982 T2 HUE029982 T2 HU E029982T2 HU E09790582 A HUE09790582 A HU E09790582A HU E09790582 A HUE09790582 A HU E09790582A HU E029982 T2 HUE029982 T2 HU E029982T2
Authority
HU
Hungary
Prior art keywords
seq
antibody
domain
domain antibody
binding
Prior art date
Application number
HUE09790582A
Other languages
English (en)
Inventor
Murray Mckinnon
Steven G Nadler
Suzanne J Suchard
Brendan Classon
Steve Holmes
Olga Ignatovich
Christopher Plummer
Steve Grant
Original Assignee
Bristol Myers Squibb Co
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE029982(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co
Publication of HUE029982T2 publication Critical patent/HUE029982T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Claims (4)

  1. Szabadni®)! igénypontök L Magába® álló inmmnglohnlin variábilis domain® antitest amely köt CD2'84toz és tartnlntaz: amioosavakat tm&yét olyan: szekvenciával rendelkeznek,, amely fel van soréivá SËQ10 )4ü::54:3«èàït (ih-239-89 k D70C). X Az \. igénypont szerinti naagában álló t®mmrsglbb®lln variábilis áontainá antitest, antely ágy va® forms&álva. hagy aöyelje· m vm> feMletldejét 3 . A 2. igénypont szeri iái magában állé irnnmaglobnlin variábilis domain!) antitest, aboi a fermaáálás tartalmazza a magában állá ímmongiöbuli®: variábilis dótosinn antitest imzzákapesolásái polietilén glikoütoz (bEO) :bEt3IMlási reakció által 4, A 3, igénypont szériáit magában állá iomtnnglohniln variábilis domains) antitest, ahol a PEö •eteefe vagy Hsán maradék; vagy ahol a f£G kMtlbelül 11) - körülbelül 50 kD; vagy ahol a magában állé ismmaglbbsdín variábilis domalnü antitestnek legalább körülbelül 24 kiD biéredlnamikar oferefe vas; vagy aboi a magában áM Immáaglbbélia variábilis domainü antitestnek legalább kMllbelöl 2M kS bídSoámamikai mérete van; vagy aböl a magiba® átlő nsnntsngfebalm variábilis dooming antitestnek in feléletideje a körülbelül 15 másodperc - körülbelül 12 óra. tartományban vas; vagy aboi a magában Ilié tnmtnaglofetili® variábilis domain® antitest tjl feléleíideje a körülbelül 12 éra - körülbelül 744 éra tartományban van. 5, A 3. Igényper® szerimi magában álló íntmnngiobniin variábilis dotnaíni antitest, ahol a magában álló inmmngibbaiin variábilis domain® antitestén kDa elágazó ídcö-hez kapcsolódik. 6, A 3. igénypont szerinti magában álló snnmmgMmis® variábilis domain® antitest, ahol a magában: álló immnsglobolin variábilis: domain® snittest 4Ö kfea Isaeáris PEG-bez kapcsolódik. I. Dnálspeeirikas ligand, amely tartalmam® az 1-6, igénypontok bármelyike szerinti, magában felé itnmnsgiobíilm variábilis dós® at ni antitestei és a magába® álló variábilis dosnainu amelynek van sntigénkölő aktivitása máshoz, mint CDS®, X A '7, igénypont szerinti duálspecillkrss Ugara!, ahol a második amígé® astlgéts, atneíy seitfeiüiet antigént vagy T sejtfelület antigént prezentál: vagy alsói a második antigén citokin,
  2. 9, Nukielnsav, amely kódol az 1-2. igénypontok szerinti tnagáfoa® álló ímmongiobnli® variábilis domalaü antitestet, vagy dttáispedftkus llgandot ?, vagy 8 igénypont szeri®!.
  3. 18, Magában áikl ínrnnmglobtílm variábilis domaisü antitest az: 1-6. igénypontok bármelyike szeri®! vagy döálspeeiriktts ligand: a 7. vagy 6, igénypont szerint felhasználásra páciens kezelésére, fen® a páciensnek vas imrmmbetegsége vagy annak kockázata fennáll II. A magában álló immunglobulin variábilis domains antitest vagy a ánáispecifekös ligand felhasználásra a ló. igénypont szerint, ahol az immsnbetegség egy aaíoitm®snbe!egSég vagy a transzpiantálnmmai kapcsolatos betegség.
  4. 12. A magában álló intnsxtnglohsrii® variábilis dóntasnti antitest vagy a dnálspeeirikns ligand felhasználásra a 1 !. igénypont szerint, áltól a trartszpiantátastatai kapcsolatos betegség ki van választva a MveíkezókMi síié: csoportból; áliotratiszpiímtátam kivetés, xenotranszpfcitáíut® kivetés, és: traaszplaniámm: gazdaszervezet ellenében! betegség; vagy sítől az antötmmanbetegség ki van választva à következőkből álló csoportból: szisztémás lapos erythemstosns, sclerosis maltlptex, riseansatold arthritis, diabétesz, psoriasis, sderoderma, SjPgrsn szindróma, atherosclerosis, gyulladásos bél betegsége morbus Crohn, és colitis alcerosa, B. Gyógyszerészei' kompozíció, amely tartalmazza az 1-6. igénypontok bármelyike szériái magában átló íonnunglobulín variábilis domains antitest vagy a: 7, vagy S. igénypont szériái daálspeclítkas ligand; terápiásán Itatásos osennyiséoéC és oyogyszerészetiíes elingadhato hordozóanyagot. ! 4. >4 13. igénypont szerinti gyógyszerészeti kompozíció, amely továbbá tartalmaz nntnnnsznppresszlyrimmanntodoiacids éstvagy gynlíadáseMem azért.
HUE09790582A 2008-07-18 2009-07-17 CD28 kötésre monovalens kompozíciók és felhasználási eljárások HUE029982T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US16212109P 2009-03-20 2009-03-20

Publications (1)

Publication Number Publication Date
HUE029982T2 true HUE029982T2 (hu) 2017-04-28

Family

ID=41226147

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE09790582A HUE029982T2 (hu) 2008-07-18 2009-07-17 CD28 kötésre monovalens kompozíciók és felhasználási eljárások
HUE13185422A HUE045249T2 (hu) 2008-07-18 2009-07-17 CD28 kötésére monovalens kompozíciók és felhasználás eljárásai

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE13185422A HUE045249T2 (hu) 2008-07-18 2009-07-17 CD28 kötésére monovalens kompozíciók és felhasználás eljárásai

Country Status (30)

Country Link
US (6) US8168759B2 (hu)
EP (2) EP2321352B1 (hu)
JP (3) JP5675608B2 (hu)
KR (2) KR101791372B1 (hu)
CN (2) CN102159590A (hu)
AR (1) AR072571A1 (hu)
AU (1) AU2009270726B2 (hu)
CA (1) CA2731220C (hu)
CL (2) CL2011000117A1 (hu)
CO (1) CO6341641A2 (hu)
CY (1) CY1121796T1 (hu)
DK (2) DK2700651T3 (hu)
EA (1) EA024585B1 (hu)
ES (2) ES2730727T3 (hu)
HK (1) HK1155178A1 (hu)
HR (2) HRP20160329T1 (hu)
HU (2) HUE029982T2 (hu)
IL (2) IL210413A (hu)
LT (1) LT2700651T (hu)
ME (1) ME02396B (hu)
MX (1) MX2011000501A (hu)
NZ (1) NZ590343A (hu)
PE (2) PE20140852A1 (hu)
PL (2) PL2321352T3 (hu)
PT (2) PT2700651T (hu)
RS (2) RS54675B1 (hu)
SI (2) SI2700651T1 (hu)
SM (1) SMT201600090B (hu)
TW (2) TW201336510A (hu)
WO (1) WO2010009391A1 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
EP2321352B1 (en) 2008-07-18 2016-01-06 Bristol-Myers Squibb Company Compositions monovalent for cd28 binding and methods of use
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
SI2401373T1 (sl) * 2009-02-25 2014-02-28 Nextera As Signalni sekvenčno neodvisen pix prikaz faga
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
EP2536764B1 (en) 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
TWI787590B (zh) * 2013-12-27 2022-12-21 日商中外製藥股份有限公司 等電點低之抗體的精製方法
BR112016018813A2 (pt) * 2014-03-19 2017-10-10 Bristol Myers Squibb Co métodos para tratar rejeição de transplante usando um anticorpo de domínio direcionado contra cd40l
CA2957354A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20170240636A1 (en) * 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
EP3806848A2 (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
EP3830579A1 (en) 2018-08-03 2021-06-09 Bristol-Myers Squibb Company Methods for detecting anti-drug antibodies
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
KR20210141544A (ko) * 2019-03-14 2021-11-23 비온드 바이오로직스 엘티디 소형 배출 차단제
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
IL294879A (en) * 2020-01-29 2022-09-01 Inhibrx Inc Monodomain antibodies of cd28 and their multivalent and multispecific constructs
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
EP4192884A1 (en) * 2020-08-04 2023-06-14 Exelixis, Inc. Pd-l1 binding agents and uses thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CA3230990A1 (en) * 2021-09-06 2023-03-09 Anna FRIDMAN-DROR Cd28 shedding blocking agents
WO2023215799A1 (en) * 2022-05-04 2023-11-09 Janux Therapeutics, Inc. Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
WO1996028143A1 (de) 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE281155T1 (de) 1998-04-20 2004-11-15 Genzyme Corp Medikamentöse verabreichung von proteinen aus polymergemischen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU4770300A (en) 1999-05-14 2000-12-05 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DK1419179T3 (da) 2001-08-10 2010-06-21 Univ Aberdeen Antigenbindingsdomæner fra fisk
US20050130124A1 (en) 2001-10-05 2005-06-16 Wiersma Erik J. Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
US7635472B2 (en) 2003-05-31 2009-12-22 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
AU2007331672A1 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
EP2321352B1 (en) 2008-07-18 2016-01-06 Bristol-Myers Squibb Company Compositions monovalent for cd28 binding and methods of use
CA2732423A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
BR112016018813A2 (pt) * 2014-03-19 2017-10-10 Bristol Myers Squibb Co métodos para tratar rejeição de transplante usando um anticorpo de domínio direcionado contra cd40l
US20170240636A1 (en) * 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Also Published As

Publication number Publication date
WO2010009391A1 (en) 2010-01-21
AR072571A1 (es) 2010-09-08
US20150299321A1 (en) 2015-10-22
PE20140852A1 (es) 2014-07-14
CO6341641A2 (es) 2011-11-21
RS54675B1 (en) 2016-08-31
JP2016063830A (ja) 2016-04-28
US9085629B2 (en) 2015-07-21
EA201100239A1 (ru) 2011-10-31
TW201336510A (zh) 2013-09-16
TW201006494A (en) 2010-02-16
HRP20190966T1 (hr) 2019-07-26
ES2562629T3 (es) 2016-03-07
JP2011528551A (ja) 2011-11-24
CA2731220A1 (en) 2010-01-21
IL210413A (en) 2017-04-30
CA2731220C (en) 2017-10-10
EP2321352B1 (en) 2016-01-06
HUE045249T2 (hu) 2019-12-30
US9908937B2 (en) 2018-03-06
CN105936648A (zh) 2016-09-14
US20180142023A1 (en) 2018-05-24
SMT201600090B (it) 2016-04-29
KR101660057B1 (ko) 2016-09-26
PL2700651T3 (pl) 2019-09-30
JP2015120695A (ja) 2015-07-02
KR101791372B1 (ko) 2017-10-27
CL2012002428A1 (es) 2013-01-11
CN102159590A (zh) 2011-08-17
HK1155178A1 (zh) 2012-05-11
DK2321352T3 (en) 2016-04-04
IL251320B (en) 2019-01-31
JP5876134B2 (ja) 2016-03-02
PE20110385A1 (es) 2011-06-22
SI2321352T1 (sl) 2016-04-29
EP2700651B1 (en) 2019-04-10
US8454959B2 (en) 2013-06-04
ES2730727T3 (es) 2019-11-12
JP6058833B2 (ja) 2017-01-11
PL2321352T3 (pl) 2016-06-30
PT2321352E (pt) 2016-03-18
EP2700651A1 (en) 2014-02-26
AU2009270726B2 (en) 2015-07-09
ME02396B (me) 2016-08-31
HRP20160329T1 (hr) 2016-04-22
EA024585B1 (ru) 2016-10-31
RS58904B1 (sr) 2019-08-30
KR20160113322A (ko) 2016-09-28
EP2321352A1 (en) 2011-05-18
SI2700651T1 (sl) 2019-08-30
IL251320A0 (en) 2017-05-29
PT2700651T (pt) 2019-06-19
US20100028354A1 (en) 2010-02-04
AU2009270726A1 (en) 2010-01-21
US20130109846A1 (en) 2013-05-02
NZ590343A (en) 2012-10-26
US8168759B2 (en) 2012-05-01
KR20110041527A (ko) 2011-04-21
CL2011000117A1 (es) 2011-06-17
IL210413A0 (en) 2011-03-31
US20210047414A1 (en) 2021-02-18
DK2700651T3 (da) 2019-07-22
CN105936648B (zh) 2020-06-16
MX2011000501A (es) 2011-05-23
CY1121796T1 (el) 2020-07-31
US20120201814A1 (en) 2012-08-09
TWI450725B (zh) 2014-09-01
LT2700651T (lt) 2019-06-25
JP5675608B2 (ja) 2015-02-25
US10919965B2 (en) 2021-02-16

Similar Documents

Publication Publication Date Title
US20210047414A1 (en) Compositions monovalent for cd28 binding and methods of use
US20130230540A1 (en) Compositions monovalent for cd28 binding and methods of use
EP2315778A2 (en) Compositions monovalent for cd28 binding and methods of use
AU2015202447B2 (en) Compositions monovalent for cd28 binding and methods of use
WO2014120916A1 (en) Pegylated domain antibodies monovalent for cd28 binding and methods of use